Syngene International Limited has informed the Exchange about Investor Presentation
Ref: Syn/CS/SE/IP/2025-26/Sept/05
September 09, 2025
To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268
Dear Sir/Madam,
Sub: Investor Presentation
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
In continuation of our earlier intimation vide reference no. Ref: Syn/CS/SE/Reg 30/2025-26/Sept/03 dated September 04, 2025 and in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation that we will be sharing with the Investors and Analysts at the meeting scheduled today, i.e., September 09, 2025.
Kindly note that no additional information will be disclosed to Analysts or Investors other than the information presented earlier and already available in the public domain.
The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.
This is for your information and records.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
_____________ Chethan Yogesh Company Secretary & Compliance Officer
Enclosed: Investor Presentation.
Phase,
B o m m a s a n d r a I n d u s t r i a l A r e a , I V
B o m m a s a n d r a I
Unit-3 plant visit for Investors – 9th September 2025
Agenda
Sr. no
Timing
Particulars
Led by
I
11:30 AM – 12:15 PM Tea + Brief Introduction (PPT) of the facility
II
12:15 PM- 1:30 PM
•
•
Divide participant in 2 groups
Visit to Drug Substance unit+ utility and facility round area for each group
Deepak Jain (CFO)
Himanshu Saxena (Head, Biologics manufacturing)
Himanshu Saxena ( Head, Biologics manufacturing)
Mr. Nainesh Dwivedi (Head, Quality for Unit-3)
Mr. Dhaval Trivedi (Head, Program Management, Biologics)
Mr. Ram Sarma (DP, Manufacturing plant head)
Mr. Satish M (DS Manufacturing plant Head)
Mr. Babu V (Engineering & maintenance, Unit-3)
III
IV
1:45 PM- 2:30 PM
Lunch / Buffer Time
2:45 PM- 3:45 PM
•
•
Feedback by Investors
Peter Bains (CEO) to join virtually
Interaction / Q&A with CFO / CEO
Deepak Jain (CFO)
Putting Science to Work
2
Syngene Management & Leadership for Unit-3 visit
Peter Bains Managing Director & CEO
Deepak Jain Chief Financial Officer
Himanshu Saxena Head, Biologics Manufacturing
• MD & CEO, Syngene International with over
3 decades of experience the pharmaceutical and biotechnology sectors
• Rejoined Syngene in Feb 2025 post spearheading
Syngene’s IPO in FY16
• Prior to joining Syngene International, Peter served
as Group CEO for Biocon
• CFO, Syngene International with over 25 years
• Over two decades of expertise in supply chain
of experience
•
Joined Syngene in September 2024, Appointed as CFO on Dec 01,2024
• Oversees the finance, supply chain, legal,
secretarial and plays an important role in driving strategy, and enabling organizational growth
management, business strategy, and pharmaceutical manufacturing
• Currently serving as Head, Biologics
manufacturing. Joined Syngene in January,2024
• Previous work experience with Cadila and Astra
Zeneca Pharma India Ltd
• Previously worked as CEO and was on the Board of Syngene for almost six years starting 2010 and led the company to its successful public listing in 2015
• Previous experience as CFO, Ather energy. Prior to that, served as India CFO for First Advantage and for Apple
• Also Served as CEO, Sosei Group, a Japanese listed
biopharmaceutical company
• Held various leadership roles at Procter & Gamble, and Ernst & Young India
• Worked in various Leadership roles for
GlaxoSmithKline over a period of 23 years
Putting Science to Work
3
01
Introduction and overview of facility
Putting Science to Work
Putting Science to Work
Background – acquired multimodal biologics facility from Stelis Biopharma with integrated drug substance and commercial DP capability in Dec 2023
Why we acquired
Immediate capacity addition Syngene’s existing capacity was fully utilized post signing 10 year agreement with Zoetis in FY23. Unit-3 added immediate capacity (20 KL of biologics drug substance capacity) with potential for future expansion up to a further 20 KL
Capability enhancement Facility includes commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing
Added drug substance capacity and drug product capability years earlier than our internal capex program
Operational Synergy Facility is located near to Biocon park which houses Syngene’s Biologics labs & other facilities enabling shared leadership and essential functions
250
200
150
100
50
0
Strengthens Syngene’s position in the fastest growing segment of the global CRDMO market
Market size* (USD bn)
8% CAGR
144
22
99
23
2023
213
39
137
37
2028
Value Buy State of the art facility acquired at Rs 617 Crores (USD 75 Mn) fully funded through internal accruals and cash
CRO
SM CDMO
LM CDMO
Overall CRDMO
Source : Frost & Sullivan: Iindependent Market Assessment of the Global and Indian CRDMO Market * Market size does not include Clinical CRO market
Putting Science to Work
5
Guidance given at time of acquisition. We are maintaining the guidance for now
Asset turnover of 1x in less than 5 years
$75m acquisition price (Acquisition concluded at gross value of Rs 617 crores. Value buy as company recorded Capital reserve due to purchase price < fair value of facility)
$10m modification capex (INR 100 Crores to repurpose and revalidate the facility)
$85m to operationalise
Operating Margin
Minor dilution of operating margins in short term as a result of costs to be incurred in this facility
EBITDA margins expected to be in line with the Company average from FY29
Contribution to PAT
Plant to positively contribute to the bottom line from FY27
Putting Science to Work
6
Current update and strategic focus - the facility was part capitalized in Q1 FY26. Focus is to drive integrated projects across human and animal health
Where are we now
Strategic focus
Received local regulatory approvals in May 2025
Focus on building pipeline across human health and animal health
Part of Unit-3 facility became operational in Q1 FY26
• 1 out 2 line in DS (8 KL 4*2 KL commissioned)
Doing Clinical projects ; delivered a GMP clinical batch of drug substance for a US based client in Q1 FY26
Seeing good client traction and response across human and animal health
Integrated clinical manufacturing projects (Both Animal & Human health) and commercial/late-stage manufacturing of mAbs over time along with drug product capabilities
Innovation for cost efficiency : Reducing cost per gram through process innovation
Putting Science to Work
7
Bird’s Eye View of Syngene Unit-3
Salient features of the multi modal facility comprising end to end DS and DP manufacturing capability
• Drug Substance (DS) :
• 8 KL (4*2 KL) commissioned
• Feasibility for perfusion
• Drug Product (DP) :
• Commercial scale, high speed, fill-finish unit
• 2 integrated vials lines: 520 vials/min
• 250 million vials annual capacity at 2 mL fill volume
• 2-100 mL fill volume feasibility
• 2 new isolator lines (100 & 600 vials/min) available for installation
• Clinical Manufacturing : 200L/500L/2000L depending on client requirement
• Quality Control (QC) : Fully equipped Lab for product quality testing
• Warehouse : Large warehouse for accommodating raw materials &
consumables
Putting Science to Work
8
Integration Journey: Acquisition to Operation in 7 Months
Production
Equipment Qualification and Area Qualification
Feb-June 2024
Equipment Qualification
July 2024
15th July test batch initiated with qualified facility and equipment, completed successfully with desired outcome.
Computer System Validation
Environmental monitoring and area qualification
Facility Modification
Acquisition
1st Dec 2023 Acquisition completed
Jan-May 2024
Infrastructure
modification
Operations
Q1 FY26
Part of Unit-3 facility became operational in Q1 FY26
Delivered a GMP clinical batch of drug substance for a US based client
Consistent Facility Performance
Multiple batches successfully executed with no facility-related issues.
Putting Science to Work
9
Unit – 3 (SU3) Site Master Plan
ETP
Block-3 200L DS,DP, QC
Utility Block -2
Block-2 2,000L DS + 2,000L DS Expansion
Utility Block -1
Entry to the site
Safety Assembly Point
Area Details
Plot area
22,000 m2 (5.4 Acres)
Block Name
Block 1
Expansion Area available
Block 2 - DS Block
2 Floors (Ground Floor+ First Floor) First floor (2 wings of 10 KL capacity each) – one DS wing operational now with 8 KL (4*2 KL commissioned)
Block 3
Clinical DS (200L), 2 DP vial lines, QC, Admin
Utility Block 1
Steam, Generator
Utility Block 2
WFI (Water for Injection)
Facilities to be visited today
Putting Science to Work
10
02
Site visit to DS / Utilities
Putting Science to Work
Putting Science to Work
Site visit – protocols
• Clothing: Minimum Gowning, Head cap & Shoe cover
• Decorum to be maintained while visiting labs
• Please limit Q&A with the technical teams related to
infrastructure, technical/plant details etc.
• We will have a separate Q&A/feedback session with Peter
and Deepak to cover strategic/financial aspects
Putting Science to Work Putting Science to Work
12 12
03
Lunch
Putting Science to Work
Putting Science to Work
04
Feedback/Q&A
Putting Science to Work
Putting Science to Work
Feedback/ Q&A
•
Feedback/thoughts on the site, capabilities, infrastructure from investors
• Open Q&A
Putting Science to Work Putting Science to Work
15 15
Thank you
© 2025 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document.
www.syngeneintl.com
Stay Connected
Putting Science to Work